Latest News and Press Releases

George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs London, UK, 3 February 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing...

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia and Central AmericaBausch Health gains exclusive rights to single-pill triple...

Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual...

London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...

George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage...

George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes GMRx4 is the second candidate to be prioritised in...